Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cardiovascular risk evaluation | Experimental | Measurement at inclusion of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 3 year follow-up |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Plasma osteoprotegerin level | Biological | dosage of plasma osteoprotegerin |
|
| Measure | Description | Time Frame |
|---|---|---|
| Occurence of at least one cardiovascular event during the 7 year follow-up according to osteoprotegerin level at inclusion | osteoprotegerin will be measured in picomol/L | 7 years after inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| Occurence of at least one cardiovascular event during the 7 year follow-up according to fibroblast growth factor 23 level at inclusion | fibroblast growth factor 23 will be measured in RU/milliliter | 7 years after inclusion |
| Occurence of at least one cardiovascular event during the 7 year follow-up according to vascular calcification score at inclusion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jean-Paul CRISTOL, Prof | Contact | +33(0)4 67 33 83 15 | jp-cristol@chu-montpellier.fr | |
| Marion Morena, PhD | Contact | +33(0)4 11 75 98 93 | m-morenacarrere@chu-montpellier.fr |
| Name | Affiliation | Role |
|---|---|---|
| Jean-Paul CRISTOL, Prof | CHU Lapeyronie, Department of Biochemistry and Hormonology, Montpellier, FRANCE | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AIDER | Recruiting | Montpellier | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Plasma fibroblast growth factor 23 level | Biological | dosage of plasma fibroblast growth factor 23 |
|
| Vascular calcification score | Procedure | measurement of vascular calcification score by multidetection computerized tomography |
|
| 7 years after inclusion |
| Mortality | 7 years after inclusion |
| Kidney functions | values of creatinine | during the 7 year follow-up |
| CHU Montpellier, Cardiology department | Active, not recruiting | Montpellier | France |
| CHU Montpellier, Endocrinology department | Recruiting | Montpellier | France |
|
| CHU Montpellier, Intensive care unit | Active, not recruiting | Montpellier | France |
| CHU Montpellier, Internal medicine department | Active, not recruiting | Montpellier | France |
| CHU Montpellier, Nephrology department | Recruiting | Montpellier | France |
|
| AIDER | Not yet recruiting | Saint-Jean-de-Védas | France |
|
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| D061205 | Vascular Calcification |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D002114 | Calcinosis |
| D002128 | Calcium Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided